🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

117+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 117 recruiting trials for “acute-myeloid-leukemia-with-t816p11p13-translocation

RecruitingNCT06452732

Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML

🏥 Peking University People's Hospital📍 2 sites📅 Started Nov 2024View details ↗
RecruitingNCT06458257

The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia

🏥 Ruijin Hospital📍 1 site📅 Started Oct 2024View details ↗
Phase 2RecruitingNCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

👨‍⚕️ Jessica K Altman, ECOG-ACRIN Cancer Research Group📍 220 sites📅 Started Sep 2024View details ↗
Phase 1, PHASE2RecruitingNCT06284486

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

👨‍⚕️ Ghayas Issa, MD, M.D. Anderson Cancer Center📍 4 sites📅 Started Sep 2024View details ↗
RecruitingNCT06458244

The Efficacy of Allo-HSCT in ND HR-CBF-AML

👨‍⚕️ Yang Shen, MD, PhD, Ruijin Hospital, Shanghai, China📍 1 site📅 Started Sep 2024View details ↗
Phase 1RecruitingNCT06357182

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

👨‍⚕️ Curtis A Lachowiez, OHSU Knight Cancer Institute📍 1 site📅 Started Aug 2024View details ↗
Phase 1RecruitingNCT06399640

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

👨‍⚕️ Somedeb Ball, MD, Vanderbilt University/Ingram Cancer Center📍 1 site📅 Started Aug 2024View details ↗
NARecruitingNCT06529250

Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

👨‍⚕️ Hui Wei, MD, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06377579

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

👨‍⚕️ Pierre PETERLIN, Dr, French Innovative Leukemia Organisation📍 21 sites📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06536959

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

🏥 Beijing 302 Hospital📍 1 site📅 Started Jul 2024View details ↗
Phase 4RecruitingNCT06571825

RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

🏥 He Huang📍 1 site📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06483906

Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.

👨‍⚕️ Xianmin Song, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Jul 2024View details ↗
EARLY_Phase 1RecruitingNCT06541405

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

👨‍⚕️ wenting Hu, Shanghai children's medical center📍 1 site📅 Started Jul 2024View details ↗
Phase 1RecruitingNCT05886049

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

👨‍⚕️ Alice S Mims, Ohio State University Comprehensive Cancer Center LAO📍 22 sites📅 Started Jun 2024View details ↗
Phase 1, PHASE2RecruitingNCT06299462

PTCy and ATG for MSD and MUD Transplants

👨‍⚕️ Leonardo J Arcuri, MD, PhD, Instituto Nacional de Cancer📍 1 site📅 Started Jun 2024View details ↗
Phase 1, PHASE2RecruitingNCT06382168

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

🏥 Delta-Fly Pharma, Inc.📍 4 sites📅 Started Jun 2024View details ↗
Phase 1RecruitingNCT06419634

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

👨‍⚕️ Bristol-Myers Squibb, Bristol-Myers Squibb📍 15 sites📅 Started May 2024View details ↗
Phase 1RecruitingNCT06465160

A Study to Evaluate the MNV-201 in Patients With Low Risk MDS

🏥 Minovia Therapeutics Ltd.📍 1 site📅 Started May 2024View details ↗
Phase 1RecruitingNCT06378437

A Study of GLB-001 in Patients With Myeloid Malignancies

👨‍⚕️ Gang Lu, Ph.D., Hangzhou GluBio Pharmaceutical Co., Ltd.📍 14 sites📅 Started May 2024View details ↗
Phase 3RecruitingNCT06387069

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

👨‍⚕️ Xiaojun Huang, Doctor, Peking University People's Hospital📍 53 sites📅 Started Apr 2024View details ↗
← PreviousPage 3 of 6Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →